摘要
玻璃体内注射抗血管内皮生长因子药物雷珠单抗（ranibizumab）治疗湿性年龄相关性黄斑变性（AMD）的有效性及安全性已得到多项临床研究证实.目前的研究主要集中在治疗方案的设计与优化方面.从早期的固定治疗模式、按需治疗模式、到近期的稳定性治疗模式和间期延长治疗模式等,治疗方案经历了从仅以视功能为标准到综合考虑视力、疾病活动性、患者依从性和整体医疗耗费等因素的变化,并仍处于不断地改进中.本文回顾了近年来有关雷珠单抗的大规模临床试验结果及相关数据分析,综述了其治疗湿性AMD的治疗方案的研究进展.
The clinical efficacy and safety of anti-VEGF therapy via intravitreal injection of ranibizumab for wet age-related macular degeneration have been proved in several clinical trials.So far studies are focus on the therapy schedule which has changed from the early fixed model,PRN model to the stability model and prolongation model recently.The criteria concerns not only visual function,but also other factors such as disease activity,patient＇ s willingness,medical cost and so on.This article reviews recent clinical trials and summarizes research progress of treatment schedule for ranibizumab therapy in wet age-related macular degeneration.
出处
《国际眼科纵览》
2014年第2期73-80,共8页
International Review of Ophthalmology
基金
北京市自然科学基金（7112031）
国家自然科学基金（81272981）
北京市卫生系统高层次卫生技术人才培养计划（2009-3-32）
